Shares of Apogee Therapeutics (APGE) surged approximately 46% in premarket trading on Monday, June 22, 2026, following a confirmed acquisition announcement. AbbVie Inc. (ABBV) announced it will acquire Apogee Therapeutics for $10.9 billion in an all-cash transaction, offering $135.11 per share.
LIXT shares surged approximately 44.4% over the last 30 days, climbing from $5.27 on May 19, 2026, to $7.61 as of June 18, 2026, driven by a transformative strategic pivot and acquisition news. The company announced a definitive agreement to acquire NOMAD Transportable Power Systems, a provider of mobile, utility-grade battery energy storage systems, and plans to rename itself NOMAD Power Solutions.
SLBT shares declined approximately 19.6% over the past 30 days, closing at $6.28 on June 17, 2026, compared to $7.81 on May 18, 2026. The stock has experienced extreme volatility following its June 15 Nasdaq debut after completing a SPAC merger with Horizon Space Acquisition II Corp.
Legend Biotech shares are down approximately 11% in premarket trading on June 18, 2026, after closing the prior session at $33.52 on June 17. The primary catalyst is the company's announced pricing of a $226 million underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS — a significant discount to the prior closing price.
RGNX shares surged 22.80% to close at $8.51 on June 17, 2026, up from the prior session's close of $6.93, marking the stock's strongest single-day gain since the May 14 selloff. Primary catalyst: Anticipation of the imminent $100 million AbbVie milestone payment , triggered upon first patient dosing in the Phase IIb/III NAAVIGATE diabetic retinopathy study, which management guided would occur in Q2 2026 — a quarter that ends in just 13 days.
QURE shares are surging approximately 84% in Wednesday's premarket session, trading near $49.79 versus a prior closing price of $26.99. The primary catalyst is a major FDA regulatory breakthrough: the agency confirmed during a recent Type B meeting that uniQure's existing 3-year Phase I/II clinical data for AMT-130 can serve as the primary basis for a Biologics License Application (BLA) under an accelerated approval pathway.
VRXA shares plummeted 56.02% to $9.35 during Tuesday's session, down from the previous close of $21.26. The primary driver is extreme post-SPAC volatility tied to an exceptionally small public float following the company's recent business combination.
NMRA shares are plunging approximately 51% in premarket trading on Monday, June 15, 2026, from a prior close of $1.78 to an indicated price near $0.87. Primary catalyst: Neumora's KOASTAL-2 and KOASTAL-3 Phase 3 trials of navacaprant in major depressive disorder (MDD) both failed to achieve statistically significant improvements on primary and key secondary endpoints versus placebo.
NUVL shares surged approximately 38.83% in premarket trading on June 9, 2026, from a prior close of $88.49 to around $122.85. The primary catalyst is a definitive acquisition agreement: GlaxoSmithKline (GSK) announced it will acquire Nuvalent for $124 per share in an all-cash tender offer. The deal values Nuvalent at approximately $10.6 billion and represents a roughly 40% premium to Monday's closing price.
TNGX shares surged approximately 47.03% in premarket trading on June 8, 2026, to around $29.73 from Friday’s closing price of $20.22. The primary catalyst is the announcement of positive initial Phase 1/2 clinical trial results for the combination of vopimetostat and daraxonrasib in pancreatic ductal adenocarcinoma, demonstrating a 92% objective response rate.
MLYS shares fell sharply, declining approximately 14.61% from the prior session close of $28.85 to a latest available price of $24.635. No single company-specific catalyst such as earnings or major announcements appears to have triggered the move.
Greenwich LifeSciences, Inc. (GLSI) shares fell sharply, declining approximately 17.56% intraday.
EDIT shares fell approximately 14.52% as of the latest available price, closing the prior session at $3.34. The primary catalyst was investor reaction to the company’s recent public stock offering announcement, raising dilution concerns.
ABVX shares fell sharply, declining approximately 44.56% from the prior session's close of $129.69. The primary catalyst was a cancer signal identified in the ABTECT Phase 3 trial for obefazimod in ulcerative colitis, overshadowing positive efficacy results.
PRAX shares are down approximately 9% in premarket trading on June 2, 2026, from the prior session close of $335.16 to an implied level near $304.99. The primary catalyst is the after-hours announcement on June 1 that the Phase 2/3 POWER1 clinical trial evaluating vormatrigine in adults with focal onset seizures failed to meet its primary endpoint — the percent change in monthly seizure frequency from baseline.
FULC shares are collapsing approximately 51% in premarket trading on June 2, 2026, from a prior close of $6.42 to a premarket price near $3.16. The sole and decisive catalyst is the company's announcement that it is permanently discontinuing its lead drug candidate, pociredir, for sickle cell disease after the FDA concluded there is no viable regulatory path forward due to malignancy risk concerns tied to the drug's mechanism of action.
CELC shares are falling sharply in premarket trading on June 2, 2026, declining approximately 22% from the prior session's close of $126.18, implying a premarket price near $98.42. The primary catalyst is the full detailed data presentation from the PIK3CA mutant cohort of Celcuity's Phase 3 VIKTORIA-1 clinical trial, delivered at the ASCO Annual Meeting in Chicago on June 2 — a long-anticipated event that appears to have triggered a "sell the news" reaction.
OCS shares plunged approximately 34.64% in after-hours and premarket trading on Monday, June 1, 2026, to around $14.84 from a prior regular-session close of $22.70 on May 29. The primary catalyst is the catastrophic failure of OCS-01, the company's lead drug candidate, in both Phase 3 DIAMOND-1 and DIAMOND-2 clinical trials in diabetic macular edema (DME).